Author + information
- Jiang Zihan1,2,3,
- Du Yin-long4,
- Geng Qiang1,2,3,
- Song Jun-xian1,2,3,
- Li Su-fang1,2,3 and
- Chen Hong1,2,3
- 1Department of Cardiology, Peking University People's Hospital, Beijing, China
- 2Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial
- 3Center for Cardiovascular Translational Research, Peking University People' s Hospital, Beijing, China
- 4PeKing University Shenzhen Hospital, Shenzhen, China
There is widespread controversy regarding the effectiveness of intra-aortic balloon pump (IABP) in acute myocardial infarction (AMI); moreover, little is known about the long term mortality. Here to evaluate the efficacy and safety for IABP in AMI patients by conducting a meta-analysis of randomized trials.
Eligible published randomized controlled clinical research (RCT) were retrieved in the Pubmed, Cochrane, Clinicaltrials.gov, China biological medical literature, Wanfang, VIP and CNKI database from 1980 to January 1st, 2016. The meta- analysis was then performed with the software of RevMan.
Of 3513 citations, a total of 15 eligible trials covering 2590 patients were collected and analyzed. Meta-analysis revealed that the incidence of early mortality (in 30-days or in-hospital) (OR 0.94, 95% CI 0.73-1.21, p=0.63), the incidence of long-term mortality (6 months or longer) (OR 0.92, 95% CI 0.72-1.19, p=0.53), the incidence of stroke (OR1.24. 95% CI0.64-2.41, p=0.52), and the incidence of re-ischemia or re-infarction (OR 0.82, 95%CI 0.41-1.65, p=0.57) of AMI patients with and without reperfusion therapy did not significantly differ between the IABP group and the non-IABP group (without reperfusion therapy: OR 1.03, 95%CI 0.33-3.24, p=0.58; with reperfusion therapy: OR 0.94, 95%CI 0.72-1.21, p=0.63). There were significant higher bleeding rates in the IABP group (OR 1.29, 95%CI 1.03-1.62, p=0.03), but there were pronounced bias.
IABP insertion is associated with no benefits with respect to either short-term or long-term survival rates in patients suffering from AMI. We also found no harm for adjunctive IABP use in AMI patients with and without cardiogenic shock.